Edwards Lifesciences
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions decreased by 6 in the most recent period (2026/Q4).
- Total institutional ownership fell 0.2 percentage points.
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 91.57% -0.24pp
- Institutions
- 1,666 -6
- As of
- 2026/Q4 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 12 buys · 38 sells
| Name | Role | Stake |
|---|---|---|
| Scott Ullem | Former Corporate VP & CFO | 0.05% |
| Larry Wood | Former Corporate VP and Group President of TAVR & Surgical Structural Heart | 0.03% |
| Donald Bobo | Corporate Vice President of Strategy & Corporate Development | 0.02% |
| Jean-Luc Lemercier | Former Corporate Vice President of Japan, Asia Pacific & Greater China | 0.03% |
| Bernard Zovighian | Chief Executive Officer | 0.02% |
| Steven Loranger | Independent Director | 0.01% |
| Kieran Gallahue | Independent Director | 0.01% |
| Nicholas Valeriani | Independent Chairperson | 0.01% |
| Leslie Heisz | Independent Director | 0.01% |
| Daveen Chopra | Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies | 0.00% |
| Ramona Sequeira | Independent Director | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-09 | Daniel Lippis | Corporate Vice President of JAPAC (Japan, Greater China & Asia Pacific) | Derivative Exercise and Sale | -619 | $72.68–104.25 |
| 2026-11-08 | Donald Bobo | Corporate Vice President of Strategy & Corporate Development | Derivative Exercise and Sale | -48,900 | $72.68–103.05 |
| 2026-11-08 | Bernard Zovighian | Chief Executive Officer | Derivative Exercise and Sale | -23,100 | $72.68–103.39 |
| 2026-10-07 | Daniel Lippis | Corporate Vice President of JAPAC (Japan, Greater China & Asia Pacific) | Derivative Exercise and Sale | -619 | $72.68–85.65 |
| 2026-09-13 | Wayne Markowitz | GM & Senior VP of Surgical Structural Heart | Sale to Issuer | -923 | $84.37–86.77 |
| 2026-09-12 | Andrew Dahl | Principal Accounting Officer, Senior VP & Corporate Controller | Sale to Issuer | -253 | $84.37 |
| 2026-09-10 | Daveen Chopra | Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies | Sale to Issuer | -398 | $86.77 |
| 2026-09-10 | Daniel Lippis | Corporate Vice President of JAPAC (Japan, Greater China & Asia Pacific) | Derivative Exercise and Sale | -619 | $72.68–87.51 |
| 2026-08-30 | Andrew Dahl | Principal Accounting Officer, Senior VP & Corporate Controller | Open Market Disposition | -544 | $91.06 |
| 2026-08-27 | Annette Bruls | Corporate Vice President of EMEA, Canada, & Latin America | Open Market Disposition | -2,644 | $89.98 |
| 2026-08-25 | Daveen Chopra | Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies | Derivative Exercise and Sale | -31,800 | $72.68–91.76 |
| 2026-08-25 | Wayne Markowitz | GM & Senior VP of Surgical Structural Heart | Open Market Disposition | -1,240 | $91.47 |
| 2026-08-10 | Daniel Lippis | Corporate Vice President of JAPAC (Japan, Greater China & Asia Pacific) | Derivative Exercise and Sale | -619 | $72.68–92.03 |
| 2026-07-29 | Scott Ullem | Former Corporate VP & CFO | Intent to Sell (Form 144) | -50,000 | $92.50 |
| 2026-07-29 | Wayne Markowitz | GM & Senior VP of Surgical Structural Heart | Open Market Disposition | -146 | $86.03 |
| 2026-07-27 | Wayne Markowitz | GM & Senior VP of Surgical Structural Heart | Derivative Exercise and Sale | -9,628 | $74.02–85.06 |
| 2026-07-26 | Bernard Zovighian | Chief Executive Officer | Other Acquisition | +319 | -- |
| 2026-07-26 | Bernard Zovighian | Chief Executive Officer | Other Disposition | -319 | -- |
| 2026-07-26 | Bernard Zovighian | Chief Executive Officer | Open Market Disposition | -2,920 | $83.93 |
| 2026-07-10 | Annette Bruls | Corporate Vice President of EMEA, Canada, & Latin America | Sale to Issuer | -109 | $92.21 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:29 · For reference only, not investment advice and not tailored to your situation.
Edwards Lifesciences discussion 0 comments